Workflow
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
IRDOpus Genetics, Inc.(IRD) GlobeNewswire·2025-03-21 13:11

Additional approximately 21milliontiedtodatareleasefortheCompany’sBEST1programRESEARCHTRIANGLEPARK,N.C.,March21,2025(GLOBENEWSWIRE)−−OpusGenetics,Inc.(“Opus”orthe“Company”)(Nasdaq:IRD),aclinical−stageophthalmicbiotechnologycompanydevelopinggenetherapiesforthetreatmentofinheritedretinaldiseases(IRDs)andtherapiesforotherophthalmicdisorders,todayannouncedthepricingofanunderwrittenpublicofferingwithgrossproceedsof21 million tied to data release for the Company’s BEST1 programRESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced the pricing of an underwritten public offering with gross proceeds of 20 million and concurrent private ...